AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
250. When You Should Worry About LDL Cholesterol with Mike Fave
Paul Saladino MD podcast
Efficacy of PCSK9 inhibitors in reducing mortality risk
1min Snip
00:00
Summary
Transcript
Episode notes
A systematic review comparing PCSK9 inhibitors showed that while alirocumab reduced the risk of all cause mortality, evolocumab did not demonstrate the same effect. Specifically, evolocumab showed an 18% increased risk of mortality in lipid-lowering trials and a 12% increased risk in clinical outcome trials. The study also revealed a higher percentage of deaths in the evolocumab group compared to the placebo group, resulting in a number needed to harm of 213 over a median follow-up of 2.2 years.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode